title: Chronic mild stress induces fluoxetine-reversible decreases in hippocampal and cerebrospinal fluid levels of the neurotrophic factor S100B and its specific receptor.
abstract: Chronic mild stress (CMS) affects the hippocampal structure and function in the rat. S100B, a calcium-binding protein secreted by astrocytes, has been shown to be increased in serum of patients with depression and associated with good therapeutic response and clinical outcome. This work aimed to study the impact of CMS and fluoxetine on depressive-like behaviors in rats, as well as the concomitant expression of the astroglial protein S100B and of its receptor RAGE (receptor for advanced glycation end products) in the hippocampus and Cerebrospinal fluid of the same group of animals. S100B and sRAGE (circulating soluble form of RAGE) were measured in CSF by ELISA, and S100B and RAGE were measured in hippocampal slices by Western blot. Our study has demonstrated that stress and depression decrease S100B and RAGE/SRAGE expression and antidepressant treatment reverses or blocks these effects. This result suggested that S100B/RAGE interactions may be involved in the development and maintenance of depression and may play an important role in the mechanism of antidepressants' therapeutic action.
authors: Department of Psychiatry, Renmin Hospital, Wuhan University, Jiefang Road 238#, Wuhan 430060, China; E-Mails: ronghansz@126.com (H.R.); rotsss@126.com (H.W.); wqrooo@yahoo.cn (Q.W.); wshjjkk@126.com (S.W.).
authors: Han
authors: H
authors: Rong
authors: Gaohua
authors: G
authors: Wang
authors: Tiebang
authors: T
authors: Liu
authors: Huiling
authors: H
authors: Wang
authors: Qirong
authors: Q
authors: Wan
authors: Senghong
authors: S
authors: Weng
references: J Biol Chem. 2000 Dec 22;275(51):40096-105
references: 11007787
references: Microsc Res Tech. 2003 Apr 15;60(6):614-32
references: 12645009
references: Eur J Neurosci. 2007 Feb;25(4):1144-54
references: 17331210
references: Brain Res. 2008 Feb 27;1196:41-52
references: 18234161
references: Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1580-3
references: 18582527
references: Eur J Pharmacol. 2001 May 25;420(2-3):R1-2
references: 11408041
references: PLoS One. 2009 Dec 15;4(12):e8309
references: 20016851
references: Neuropharmacology. 2008 Mar;54(3):530-41
references: 18164735
references: Neurosci Lett. 2009 May 22;455(3):178-82
references: 19429116
references: J Neurotrauma. 2005 Jun;22(6):645-55
references: 15941374
references: Psychopharmacology (Berl). 1987;93(3):358-64
references: 3124165
references: Biochim Biophys Acta. 2000 Dec 20;1498(2-3):99-111
references: 11108954
references: Int J Biochem Cell Biol. 2001 Jul;33(7):637-68
references: 11390274
references: Arthritis Rheum. 2007 Dec;56(12):4174-81
references: 18050248
references: J Psychiatry Neurosci. 2000 Mar;25(2):167-77
references: 10740990
references: Neuropsychopharmacology. 2004 Nov;29(11):2007-17
references: 15266352
references: J Neurosci. 2000 Dec 15;20(24):9104-10
references: 11124987
references: Eur J Pharmacol. 2004 Sep 13;498(1-3):135-42
references: 15363987
references: Curr Neurovasc Res. 2004 Jul;1(3):261-7
references: 16181076
references: Cell. 1999 Jun 25;97(7):889-901
references: 10399917
references: Neuropsychobiology. 2001;44(2):88-90
references: 11490177
references: Eur Neuropsychopharmacol. 2003 Aug;13(4):235-9
references: 12888182
references: Biol Psychiatry. 2006 Feb 15;59(4):309-16
references: 16154542
references: Biochem Pharmacol. 2010 May 15;79(10):1379-86
references: 20096667
references: Biol Psychiatry. 2000 Oct 15;48(8):766-77
references: 11063973
references: J Neurosci. 2008 Oct 22;28(43):10928-36
references: 18945900
references: Neurosci Lett. 2004 Jan 2;354(1):69-73
references: 14698484
references: Neuroreport. 2003 Aug 6;14(11):1471-3
references: 12960766
references: Biol Psychiatry. 2008 Aug 15;64(4):293-301
references: 18406399
references: Restor Neurol Neurosci. 2003;21(3-4):97-108
references: 14530573
references: Curr Med Chem. 2009;16(8):940-52
references: 19275604